ArticleAddictive behaviors2022
Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults.
Article in Addictive behaviors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.Current topics in behavioral neurosciences · 2026Pooled it
- Substance Use Patterns Across the Sexual Identity Spectrum Among U.S. Individuals.The American journal of psychiatry · 2026Article
- Association Between Lifetime Hallucinogen Use and Valvular Heart Disease: Findings from the All of Us Research Program.Journal of psychoactive drugs · 2026Article
- Cannabis and Psychedelics Among U.S. Young Adults: Use, Messaging Exposure, Perceptions, and Legalization Support.International journal of environmental research and public health · 2026Article
- Intermittent MDMA Attenuates Ovariectomy-induced Bone Loss via a Gut Microbiota-Bone Axis.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Article
- Understanding Suicidal Thoughts and Behaviors Among LGBTQ + Youth: Differential Associations Between Bullying and Substance Use.Prevention science : the official journal of the Society for Prevention Research · 2025Article
- Psychedelics and Suicide-Related Outcomes: A Systematic Review.Journal of clinical medicine · 2025Review
- Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Association of Hallucinogen Use With Psychosocial Outcomes: Secondary Analysis of the Spinal Cord Injury Model Systems Database.Topics in spinal cord injury rehabilitation · 2025Article
- Article
- Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.Harm reduction journal · 2022Article
- Prevalence and Correlates of Past Year Ecstasy/MDMA Use in the United States.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThere is renewed interest in the clinical application of hallucinogenic substances to treat a range of psychiatric conditions. However, there is mixed evidence regarding how use of such substances outside of medical settings relates to psychological distress, depression, and suicidality.
methodsWe examined data from a US representative sample of noninstitutionalized adults from the 2015-2020 National Survey on Drug Use and Health (N = 241,675). We evaluated whether past-year use of specific hallucinogens (i.e., LSD, DMT/AMT/Foxy, salvia divinorum, ecstasy [MDMA/Molly], ketamine) is associated with reporting past-year serious psychological distress (SPD), major depressive episode (MDE), and suicidality. Generalized linear models using Poisson and log link were used to estimate adjusted prevalence ratios (aPRs), controlling for sociodemographic characteristics and past-year use of various other illegal drugs.
resultsLSD use was associated with an increased likelihood of MDE (aPR = 1.23, 95% CI: 1.10-1.37) and suicidal thinking (aPR = 1.21, 95% CI: 1.09-1.34). Similar associations were observed between salvia divinorum use and suicidal thinking (aPR = 1.41, 95% CI: 1.00-1.97) and between DMT/AMT/Foxy use and suicidal planning (aPR = 1.81 95% CI: 1.17-2.81). On the other hand, ecstasy use was associated with a decreased likelihood of SPD (aPR = 0.83, 95% CI: 0.77-0.89), MDE (aPR = 0.91, 95% CI: 0.83-1.00), and suicidal thinking (aPR = 0.86, 95% CI: 0.75-0.99).
conclusionFindings suggest there are differences among specific hallucinogens with respect to depression and suicidality. More research is warranted to understand consequences of and risk factors for hallucinogen use outside of medical settings among adults experiencing depression or suicidality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.